Compositions and Methods to Regulate Renalase in the Treatment of Cancer

Patent metadata

Field	Value
Publication number	US-2021024652-A1
Application number	US-202016847964-A
Country	US
Kind code	A1
Filing date	Apr 14, 2020
Priority date	Jun 26, 2014
Publication date	Jan 28, 2021
Grant date	—

Abstract

The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.

First claim

1 - 36 . (canceled)

37 . A composition comprising an isolated monoclonal antibody, wherein the antibody comprises: a) the heavy chain CDR1 sequence of SEQ ID NO:19; b) the heavy chain CDR2 sequence of SEQ ID NO:20; c) the heavy chain CDR3 sequence of SEQ ID NO:21; d) the light chain CDR1 sequence of SEQ ID NO:22; e) the light chain CDR2 sequence of SEQ ID NO:23; and f) the light chain CDR3 sequence of SEQ ID NO:24.

38 . The composition of claim 37 , wherein the antibody specifically binds to renalase with an affinity of at least 10′ M.

39 . The composition of claim 37 , wherein the antibody specifically binds a peptide sequence as set forth in SEQ ID NO:4.

40 . The composition of claim 37 , wherein the antibody is selected from the group consisting of an immunoconjugate, a defucosylated antibody, and a bispecific antibody.

41 . The composition of claim 40 , wherein the immunoconjugate comprises a therapeutic agent or a detection moiety.

42 . The composition of claim 37 , wherein the antibody is selected from the group consisting of a humanized antibody, a chimeric antibody, a fully human antibody, and an antibody mimetic.

43 . The composition of claim 37 , wherein the antibody comprises a heavy chain sequence as set forth in SEQ ID NO:17.

44 . The composition of claim 37 , wherein the antibody comprises a light chain sequence as set forth in SEQ ID NO:18.

45 . A method of treating or preventing a disease or disorder associated with renalase in a subject, the method comprising the step of administering to the subject the composition of claim 37 .

46 . The method of claim 45 , wherein the composition is administered to the subject in combination with a second therapeutic agent.

47 . The method of claim 45 , wherein the disease or disorder associated with renalase is selected from the group consisting of renal disease, cardiovascular disease, cancer, and any combination thereof

48 . The method of claim 47 , wherein the disease or disorder is cancer, and the cancer is pancreatic cancer or melanoma.

Assignees

• Univ Yale

Inventors

• Desir Gary
• Hunt Abigail
• O-Rear Jessica
• Flynn Peter

Classifications

• G01N2333/90209

  acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4) · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title